Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes over Time Celalettin Ustun, Jiří Slabý, Ryan M. Shanley, Jan Vydra, Angela R. Smith, John E. Wagner, Daniel J. Weisdorf, Jo-Anne H. Young Biology of Blood and Marrow Transplantation Volume 18, Issue 10, Pages 1580-1588 (October 2012) DOI: 10.1016/j.bbmt.2012.04.012 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Frequency of human parainfluenza virus (HPIV) infections per season. Biology of Blood and Marrow Transplantation 2012 18, 1580-1588DOI: (10.1016/j.bbmt.2012.04.012) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Trends of infection characteristics over time. Biology of Blood and Marrow Transplantation 2012 18, 1580-1588DOI: (10.1016/j.bbmt.2012.04.012) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 3 Incidence of human parainfluenza virus (HPIV) by year and conditioning intensity. Biology of Blood and Marrow Transplantation 2012 18, 1580-1588DOI: (10.1016/j.bbmt.2012.04.012) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 4 (A) Lower respiratory tract infection (LRTI) with human parainfluenza virus (HPIV) is associated with higher mortality than upper respiratory tract infection (URTI). (B) Higher mortality with early onset (<30 days) of LRT-HPIV. (C) Effect of antiviral treatment for LRT-HPIV on survival. Abbreviations: IVIG = intravenous immune globulin. Biology of Blood and Marrow Transplantation 2012 18, 1580-1588DOI: (10.1016/j.bbmt.2012.04.012) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions